Amplia Therapeutics (ASX:ATX) has taken a step forward in its clinical expansion strategy, announcing the opening of two U.S. trial sites for its AMPLICITY pancreatic cancer study.
Amplia expands U.S. footprint as AMPLICITY pancreatic cancer trial gains momentum
February 11, 2026 Australian Biotech
Latest Video
New Stories
-
Setting the standard for safe and accountable virtual healthcare in Australia
March 4, 2026 - - Latest News -
A system built for a past is struggling to meet the challenge of today, let alone the future
March 4, 2026 - - Latest News -
Firebrick Pharma targets breakout year in 2026 as Nasodine expansion accelerates
March 4, 2026 - - Australian Biotech -
AdAlta strengthens clinical push for breakthrough solid cancer therapy
March 4, 2026 - - Australian Biotech -
Island Pharmaceuticals deepens US biodefence ties to advance Marburg treatment
March 4, 2026 - -
PYC Therapeutics secures strong backing as retail offer adds $47 million to capital raise
March 4, 2026 - - Australian Biotech -
Alterity strengthens clinical leadership with appointment of neurologist Daniel Claassen
March 4, 2026 - - Australian Biotech

